Published in Sci Rep on February 23, 2016
Bicalutamide in Treating Patients With Metastatic Breast Cancer | NCT00468715
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Sci Rep (2017) 1.40
Prohibitin promotes androgen receptor activation in ER-positive breast cancer. Cell Cycle (2017) 0.75
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Int J Biol Sci (2016) 0.75
The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis. Oncotarget (2017) 0.75
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature (2003) 17.52
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 17.38
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev (2006) 8.48
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (1998) 4.74
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
Transcriptional activation by BRCA1. Nature (1996) 3.64
Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem (2008) 3.52
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature (2011) 3.30
Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98
Basal-like breast cancer and the BRCA1 phenotype. Oncogene (2006) 2.62
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1999) 2.43
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene (2006) 2.09
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol (2009) 1.94
The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res (2005) 1.93
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
Nuclear receptor minireview series. J Biol Chem (2001) 1.57
Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene (2005) 1.57
BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell (2011) 1.48
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol (2007) 1.28
The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res (2010) 1.25
The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res (2006) 1.12
Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab (2011) 1.07
Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol (2014) 1.04
Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr (2010) 0.93
An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells. J Cell Sci (2008) 0.93
Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer (1996) 0.93
Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer. Oncotarget (2014) 0.91
Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. Prostate (2013) 0.87
BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. Oncotarget (2015) 0.87
TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer. Oncotarget (2015) 0.82
BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. Oncotarget (2015) 0.87
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Int J Biol Sci (2016) 0.75
MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. Lung Cancer (2014) 0.75